Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 115-120

  Reaume, M Neil ^a,b   Leighl, Natasha B ^a,c   Mittmann, Nicole ^a,d   Coyle, Doug ^a,e   Hirsh, Vera ^a,f   Seymour, Lesley ^a   Tu, Dongsheng ^a   Shepherd, Frances A ^a   Graham, Barbara ^a   Gridelli, Cesare ^a,g   Perrone, Francesco ^a,g   Di Maio, Massimo ^a   Bradbury, Penelope A ^a   Evans, William K ^a,h  

^a Clinical Trials Group   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d HOPE Research Centre   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Cost consequence; Economic analysis; Non platinum doublet; Non small cell lung cancer; Platinum doublet

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE;

ADVANCED CANCER; ALLERGY; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CONSTIPATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HAIR LOSS; HEARING DISORDER; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEPHROTOXICITY; OVERALL SURVIVAL; PATENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

COST CONSEQUENCE; ECONOMIC ANALYSIS; NON-PLATINUM DOUBLET; NON-SMALL CELL LUNG CANCER; PLATINUM DOUBLET;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84884414702     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.07.012     Document Type: Article

References (30)

1. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2012, Toronto, Canada; 2012.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
3. Sandler A. Significantly higher survival with Gemcitabine-cisplatin vs. cisplatin in advanced non-small cell lung cancer (NSCLC): final results from an international phase III study 1998.
4. Non-small Cell Lung Cancer Collaborative G. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br Med J 1995, 311(7010):899.
5. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Oncol. 1994, 12(2):360. [see comment].
6. Bonomi P., Kim K., Kusler J., Johnson D. Cisplatin/etoposide vs. paclitaxel/cisplatin/G-CSF vs. paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Huntington) 1997, 11(4 (Suppl. 3)):9-10.
7. Kelly K., Crowley J., Bunn P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19(13):3210.
8. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92.
9. Gridelli C., Frontini L., Perrone F., Gallo C., Gulisano M., Cigolari S., et al. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators 2000, 83(6):707.
10. Hirsh V., Langleben A., Ayoub J., Cormier Y., Pintos J., Iglesias J.L. Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial. Cancer 2001, 92(4):830.
11. Lilenbaum R., Cano R., Schwartz M., Siegel L., Lutzky J., Lewis M., et al. Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study. Cancer 2000, 88(3):557.
12. Gridelli C., Gallo C., Shepherd F.A., Illiano A., Piantedosi F., Robbiati S.F., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21(16):3025.
13. Evans W.K., Will B.P., Berthelot J.M., Wolfson M.C. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 1995, 72(5):1270.
14. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
15. Ortega A., Dranitsaris G., Puodziunas A. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Technol Assess Health Care 1998, 14(4):788.
16. Ontario Health Insurance (OHIP) schedule of benefits and fees 1999, Ontario Ministry of Health and Long Term Care, Toronto, Canada, [updated October 2009].
17. Institute of Health E. A National List of Provincial Costs for Health Care: Canada 1997/8; 2000.
18. Amin M., Fergusson D., Wilson K., Tinmouth A., Aziz A., Coyle D., et al. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada. Transfusion 2004, 44(10):1479.
19. Statistics C. Consumer price index, historical summary 2005.
20. Rapp E., Pater J.L., Willan A., Cormier Y., Murray N., Evans W.K., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988, 6(4):633.
21. Dranitsaris G., Cottrell W., Evans W.K. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer. Curr Opin Oncol 2002, 14(4):375.
22. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005, 23(13):2926-2936.
23. Rajeswaran A., Trojan A., Burnand B., Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008, 59(January (1)):1-11.
24. Laupacis A., Feeny D., Detsky A.S., Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992, 146(4):473.
25. Berry S.R., Bell C.M., Ubel P.A., Evans W.K., Nadler E., Strevel E.L., et al. Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs. J Clin Oncol 2010, (August). [Epub ahead of print].
26. Evans W.K., Coyle D., Gafni A., Walker H. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis. Chronic Dis Can 2003, 24(4):102.
27. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2007, 355(24):2542-2550.
28. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674):1525-1531.
29. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14(March (3)):253-263.
30. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 Sep 3, 361(10):947-957.